Webinars

Webinars Back to resource centre 11 January 2023 Novel Digital Technologies and Biomarkers to Characterise Depression Novel digital biomarkers have the potential to quantify commonly reported symptoms from patients that have been often difficult to characterize and span across many diagnostic groups. Here we explore several of these technologies alongside leaders from Novartis in the webinar ‘Novel digital technologies and biomarkers

Webinars Back to resource centre 11 January 2023 Digital Health Event 2021: Integrating multimodal data to meet clinical challenges As novel tools to measure health proliferate, understanding how to tackle multimodal data streams is key. During Cambridge Cognition's fifth annual digital health event, expert panelists shared how additional data streams are shaping their work and how clinical researchers can best position

Webinars Back to resource centre 11 January 2023 Voice Technology in Clinical Trials Forecasts suggest that by 2024 the number of digital voice assistants will reach 8.4 billion units – a number higher than the world’s population. However, as these devices are built for commands rather than cognitive testing, how can clinical trials benefit from the technology? In this webinar,

Webinars Back to resource centre 11 January 2023 Virtual clinical trials: What have we learned in the era of Covid-19? Industry experts working at the forefront of drug development and digital health share lessons learned delivering virtual trials during the Covid-19 pandemic. Catch up on a thought-leading discussion on how to mature the accelerated adoption of digital trials during lockdown

Webinars Back to resource centre 11 January 2023 Remote Cognitive Testing and Lessons Learned During Lockdown Traditionally, scientists assess cognition with thorough, but infrequent, testing sessions in a tightly controlled laboratory environment. In efforts to curb Covid-19 transmission rates, most researchers have postponed this form of face-to-face assessment. Between the longevity of this pandemic-driven lockdown, and the significant risk of

Webinars Back to resource centre 11 January 2023 Wearable Technology for High-Frequency Cognitive and Mood Assessments in Depression Despite the obvious advantages of conducting thorough assessments in highly controlled laboratory environments, the associated resource burden means that such lengthy assessments are out of the question for daily testing. The widespread adoption of smartphones and wearables makes monitoring symptoms in real

Webinars Back to resource centre 11 January 2023 Elderly patients in clinical trials: addressing the evidence-practice gap Despite carrying the largest burden of chronic diseases and taking more prescription medications than any other group, older adults are consistently under-represented in clinical trials. The complex, and therefore risky, treatment needs associated with older adults is often what makes sponsors hesitant to

Webinars Back to resource centre 11 January 2023 Future directions in eCOA: Innovations in high-frequency and automated voice-based testing As drug development programmes increasingly demand real-world data collection – are the current eCOA instruments fit for purpose? Which innovations will change the landscape, what are the challenges and how might we overcome them? In this webinar Chief Technology Officer at

Webinars Back to resource centre 11 January 2023 Pro-cognitive drug trial failures in schizophrenia: the need for cognitive screening? Despite a wealth of research, pharmaceutical companies have thus far been unsuccessful in their attempts to address cognitive impairment in schizophrenia. This begs the question: are these compounds truly ineffective or has trial methodology itself been a limiting factor in successfully

Webinars Back to resource centre 11 January 2023 Cognitive Safety: Satisfying Regulatory Requirements in a Competitive Landscape Common disease states, environmental toxins, certain medications and the aging process itself can all compromise the integrity of the BBB. Accordingly, both central nervous system (CNS) and non-CNS therapeutics (e.g. for cardiovascular disease, diabetes, cancer, pain) can present significant challenges for cognitive safety